The impact of advanced age on anticoagulant therapy for acute venous thromboembolism.
Ludovic LafaieThomas CélarierManuel MonrealPatrick MismettiXavier DelavenneLaurent BertolettiPublished in: Expert opinion on drug metabolism & toxicology (2022)
DOACs have become an essential part of the management of VTE in the elderly, both for their efficacy and safety. However, we are faced with a list of unmet needs, such as the relevance of DOACs in the very elderly, cancer patients, and those with renal impairment. Clinicians and pharmacists must remain cautious about comedications, as well as about the patient's comorbidities.